谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC).

Melissa Lynne Johnson, William Fox,Yun-Gyoo Lee,Ki Hyeong Lee,Hee Kyung Ahn,Young-Chul Kim,Kang-Yun Lee,Jong-Seok Lee, Xian He, Christine Park, Debbie Pomponio, Thao Dang,Patrick Hoang Phuong,Dimitry S. A. Nuyten,Aparna Madhukeshwar Hegde,Rohit Joshi

Journal of Clinical Oncology（2022）

引用 0|浏览14
暂无评分
关键词
lung cancer,zimberelimab,domvanalimab,first-line,non-small
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要